A Pivotal CBL-0302 Phase 3 study for subcutaneous fat reduction
Latest Information Update: 17 Mar 2025
At a glance
- Drugs CBL-514 (Primary)
- Indications Adiposis dolorosa; Cellulite; Obesity
- Focus Adverse reactions; Registrational
Most Recent Events
- 12 Mar 2025 According to Caliway Biopharmaceuticals media release, subject recruitment expected in Q3 2025.
- 10 Feb 2025 According to a Caliway Biopharmaceuticals media release, company plans to initiate subject recruitment for this pivotal global Phase 3 study in the second half of 2025.
- 31 Jan 2024 New trial record